Ivabradine Tablet
NDC Package 70710-1472-8

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Ivabradine tablets are contraindicated in patients with:Acute decompensated heart failureClinically significant hypotensionSick sinus syndrome, sinoatrial block or 3rddegree AV block, unless a functioning demand pacemaker is presentClinically significant bradycardia [see Warnings and Precautions (5.3)]Severe hepatic impairment [see Use in Specific Populations (8.6)]Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions (7.3)]Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions (7.1)]. This formulation utilizes a tablet delivery system. Marketed by Zydus Pharmaceuticals Usa Inc., this product is identified by NDC 70710-1472 and is authorized under FDA application ANDA213442.

Identification & Billing

NDC Package Code
70710-1472-8
Package Description
180 TABLET in 1 BOTTLE
Product Code
70710-1472
11-Digit Billing Format
70710147208
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Ivabradine
Non-Proprietary Name
Ivabradine
Substance Name
Ivabradine Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
IVABRADINE HYDROCHLORIDE 7.5 mg/1
Pharmacologic Class
Usage Information
Ivabradine tablets are contraindicated in patients with:Acute decompensated heart failureClinically significant hypotensionSick sinus syndrome, sinoatrial block or 3rddegree AV block, unless a functioning demand pacemaker is presentClinically significant bradycardia [see Warnings and Precautions (5.3)]Severe hepatic impairment [see Use in Specific Populations (8.6)]Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions (7.3)]Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions (7.1)]

Regulatory & Marketing

Labeler Name
Zydus Pharmaceuticals Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA213442
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-02-2024
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70710-1472). Click a package code to view its specific billing and regulatory data.

70710-1472-6
60 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70710-1472-8 identifies a specific commercial package of 180 tablet in 1 bottle of Ivabradine, a human prescription drug labeled by Zydus Pharmaceuticals Usa Inc.. This tablet is formulated for oral use and contains ivabradine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Pharmaceuticals Usa Inc. on July 02, 2024. The current certification is valid through December 31, 2026.

How is this Zydus Pharmaceuticals Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70710147208. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70710-1472-8
11-Digit CMS (5-4-2)
70710-1472-08

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.